Move to topTop
April 26, 2022
Terumo Aortic announced today the enrolment of patients in an all-comers Abdominal Aortic Aneurysm (AAA) Study of the TREO Abdominal Stent-Graft System in the United States.

The TREO Abdominal Stent-Graft System is approved by the US Food and Drug Administration (FDA) to treat patients with abdominal aortic aneurysms. This is a prospective, multi-center, non-randomised, single-arm, post-market study; the purpose is to evaluate the real world, long-term performance of the device as a treatment for patients with infrarenal abdominal aortic aneurysms or aorto-iliac aneurysms.

Enrolment has now passed the 50% milestone to recruit a minimum of 300 patients who have had the TREO Abdominal Stent-Graft System implanted at up to 55 investigational sites in the United States. All patients will be followed for 5 years.

As the leading study enroller and Principal Investigator, Jeromy Brink, MD, Vascular and Endovascular Surgeon, Banner University Medical Center, Phoenix, Arizona commented: “The all-comers scope of this study compared with the pre-market study provides the opportunity to review data from a much larger patient population resulting in a far better understanding of the device and how it performs over an extended period of time.”

Jeffrey Mifek, Global Vice President, Clinical and Medical Affairs at Terumo Aortic added: “Over the next few years, the primary objective of this study is to collate real world safety and effectiveness data of TREO and provide insights into long-term performance. The data collected may allow for expanded indications of this device to treat a wider group of patients.”

TREO received CE Mark approval in 2015, FDA approval in 2020 and PMDA approval in 2021. This device is integral to Terumo Aortic’s innovative portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.
About Terumo Aortic
At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.
 
Note to Editors
  • Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical Inc. in 2017
  • Terumo Aortic has over 1,250 employees around the world with manufacturing facilities in Glasgow, Scotland and Sunrise, Florida.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.